Companies

Lilly vs. Novo Nordisk: The Obesity Drug War From Lilly's Side

Eli Lilly arrived five years late and took the lead anyway. Here is how the Indianapolis company played it, where it is losing, what it agreed with the Trump administration, and why both companies are now suing each other over advertising.

Last verified September 14, 2026·15 sources cited

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Novo Nordisk got there first. Ozempic was approved in 2017, Wegovy in 2021. Eli Lilly did not have a weight-loss drug on the US market until November 2023.

Within about three years, Lilly was the bigger company in this market by almost every measure. By the second quarter of 2026 it held 60.9% of the US incretin market against Novo Nordisk’s 38.8%, by Lilly’s own count in its earnings presentation [1].

This is the story of how a company that arrived late won the injection market, and where it is still losing.

How did Lilly catch up so fast?

Three decisions, roughly in order of importance.

It built factories before it had a product. Lilly started committing capital to manufacturing in 2020, driven by early tirzepatide trial results, years before Mounjaro was approved in 2022 or Zepbound in 2023. The company has described this as a decision taken “at risk.” It meant that when demand arrived, Lilly could eventually meet it. Since 2020 it has committed more than $50 billion to US capital expansion and built 11 new American plants [2].

It ran the head-to-head trial. In December 2024, Lilly reported SURMOUNT-5, a trial that put Zepbound directly against Wegovy. Average weight loss was 20.2% with tirzepatide against 13.7% with semaglutide [3]. Full results were published in the New England Journal of Medicine in May 2025. That single number has done more commercial work for Lilly than any advertisement, and it is now the subject of a lawsuit, which we will come to.

It went direct to patients. LillyDirect launched on January 4, 2024, the first direct-to-patient platform from a major drugmaker. It sells Zepbound at a published self-pay price, lists independent telehealth providers, and since October 2025 offers pickup at nearly 4,600 Walmart pharmacies. Self-pay accounted for about 45% of Zepbound prescriptions in the first quarter of 2026.

There was a fourth factor that Lilly did not control but benefited from enormously: Novo Nordisk’s 2025 crisis. The Danish company cut guidance, changed chief executives, overhauled its board and announced about 9,000 job cuts while Lilly was raising guidance every quarter.

Where is Lilly losing?

Pills, decisively.

Novo Nordisk got the Wegovy pill approved in December 2025 and launched it on January 5, 2026. Lilly’s Foundayo was approved April 1, 2026, began shipping through LillyDirect on April 6 and was broadly available from April 9. Three months is not a long head start, but it has been enough.

In the second quarter of 2026, the Wegovy pill generated about $496 million worldwide. Foundayo generated $98 million, of which $67 million was in the United States and $31 million in the United Arab Emirates [4][5]. Analyst consensus had been around $130 million. Weekly prescription data compiled by IQVIA and cited by Citi and Jefferies told the same story: at week 13 of its launch, Foundayo was running about 19,550 weekly prescriptions against more than 105,000 for the Wegovy pill at the same point [4].

Two structural reasons explain most of it.

First, brand familiarity. Novo’s pill is the same molecule as its injection, under a name every prescriber already knew. Foundayo is orforglipron, a genuinely new compound with a brand name nobody had heard before April 2026.

Second, coverage timing. Novo had coverage from the major pharmacy benefit managers from the first week. Lilly did not secure access across all three until June 2026 [4].

There is a third reason that cuts closer to the bone: at 72 weeks, oral Wegovy produced about 16.6% weight loss in its trials against about 11.2% for Foundayo. No head-to-head trial has compared them. But BMO Capital Markets read the early numbers as patients “prioritizing efficacy over convenience” [5].

Lilly’s counter-argument is real. Foundayo is a small molecule, not a peptide, which means it can be taken at any time of day without the fasting protocol oral semaglutide requires. Lilly’s US commercial head, Ilya Yuffa, said in August 2026 that the company was “starting to see an inflection point,” that volume had doubled in a month and that Foundayo was accounting for nearly one in four new patient starts [4].

It is also worth remembering that Novo dominated the injection market at first, too.

What did Lilly agree with the Trump administration?

On November 6, 2025, Lilly and the White House announced a deal that reshaped US obesity drug pricing [6].

The core terms:

Zepbound, and orforglipron if approved, would cost Medicare beneficiaries no more than $50 a month, which Lilly said could begin as early as April 1, 2026. Medicare’s coverage of these medicines for obesity actually went into effect on July 1, 2026, reaching roughly 40 million people. States could extend the same access through Medicaid.
LillyDirect self-pay prices fell by $50, putting the Zepbound starting dose at $299 a month, and orforglipron would start at $149.
Emgality, Trulicity and Mounjaro would be offered on LillyDirect at 50% to 60% off list price.
Lilly’s $35 insulin cap continues.
Commercial insurance pricing was not part of the agreement.

In exchange, Lilly received three years of relief from pharmaceutical tariffs and reaffirmed more than $50 billion of US manufacturing investment [6]. Novo Nordisk signed a parallel agreement the same day, with Medicare and Medicaid pricing for both companies set around $245 a month and a $50 patient copay [7].

David Ricks called it “a pivotal moment in U.S. health care policy and a defining milestone for Lilly, made possible through collaboration with the Trump Administration” [6].

The tariff half of that bargain became concrete on April 2, 2026, when a presidential proclamation under Section 232 imposed a default 100% tariff on imported patented pharmaceuticals. The proclamation set a tiered structure: 20% for companies with an approved onshoring plan, and zero until January 20, 2029 for companies that have both an onshoring plan and a most-favored-nation pricing agreement [8]. Lilly qualified on both counts. Its main overseas manufacturing base is Ireland, so without that exemption the exposure would have been substantial.

Whether you read this as a company lowering prices for patients or as a company trading price concessions for trade protection depends on your politics. Both descriptions are accurate.

Why did the FDA warn Lilly about its advertising?

On September 9, 2025, the same day President Trump signed an executive order on disclosure in direct-to-consumer prescription drug advertising, the FDA issued Lilly three warning letters [9][10].

Two covered local television interview segments in Oklahoma City and Dayton, in which Lilly executives discussed Zepbound and LillyDirect. The FDA said these videos “entirely omit risk information.”

The third covered “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” which aired on ABC on March 18, 2024 and later on Hulu. The FDA said the program minimized the risks of Zepbound and Mounjaro, including the boxed warning for thyroid C-cell tumors and the contraindication for people with a personal or family history of multiple endocrine neoplasia type 2. It singled out a paid consultant’s on-air statement that concerns about pancreatitis, gallbladder complications and thyroid cancer had attracted “a lot of hype” and that “the risk is less than 1%” [9].

“The video not only omits several serious and significant risks, it also understates the safety profile of these drugs,” the FDA wrote [9].

Novo Nordisk received a matching letter over the same broadcast. Lilly told Reuters that the letters covered interviews conducted by independent media outlets, that the interviews were not advertisements, and that it had no editorial control over them [10].

Why are Lilly and Novo Nordisk suing each other?

Because advertising is where the fight moved once the science stopped settling it.

On July 21, 2026, Novo Nordisk sued Lilly and Lilly USA in the US District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act [11][12].

Novo’s argument: Lilly’s national campaigns compare the highest approved doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic, while omitting newer approved doses. Specifically, Lilly’s Zepbound ads rest on SURMOUNT-5, which tested 10 and 15 mg of Zepbound against 1.7 and 2.4 mg of Wegovy. In March 2026 the FDA approved a 7.2 mg dose of Wegovy. In the STEP UP trial that dose produced 18.7% average weight loss at 72 weeks, against 15.6% for the 2.4 mg dose and 3.9% for placebo [18]. Novo says Lilly’s ads acknowledge the higher dose only in footnotes it describes as “virtually invisible,” and that the campaign has been served more than 700 million times since Lilly modified it following an April cease-and-desist letter [11][12].

Lilly’s argument: SURMOUNT-5 is a real head-to-head randomized trial, the only one that has ever directly compared these two drugs in weight management. “The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial,” the company said. “It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available” [12].

Both positions are defensible, and that is the useful thing for a reader to understand. Lilly is citing a genuine trial. Novo is pointing out that the trial predates its own stronger dose. And there is no head-to-head trial comparing the highest approved doses of both drugs, which means nobody can currently say with certainty which is more effective at maximum dose.

Novo is seeking an injunction, corrective advertising and damages.

What about the compounding fight?

Lilly has run a parallel campaign against compounded tirzepatide, and it is a different kind of story.

Compounded tirzepatide existed legally because tirzepatide injection was on the FDA drug shortage list from December 15, 2022. The FDA declared the shortage resolved on October 2, 2024, reconsidered after a lawsuit, then reaffirmed the decision in a formal order on December 19, 2024, ending the legal basis for most compounding [13].

Lilly did not wait for that to finish. In April 2025 it sued four telehealth companies, Fella Health, Willow Health, Henry Meds and Mochi Health, in California federal courts, alleging false advertising, unfair competition and, for some defendants, unlicensed practice of medicine. The central claim was that mass-produced formulations were being marketed as “personalized” [14]. It has also sued compounding pharmacies including Strive and Empower.

The results have been genuinely mixed. A court allowed the “personalized” advertising claim against Henry Meds to proceed in September 2025 but dismissed a broader claim. A judge dismissed Lilly’s case against Willow Health with prejudice in February 2026. In April 2026 a judge allowed amended claims against Mochi Health to proceed, and on September 8, 2026 US District Judge Jacqueline Scott Corley trimmed the case again on the second amended complaint, dismissing the Lanham Act claims against both Mochi Health and its supplier Aequita Pharmacy while letting the claims that they conspired to compete unfairly with Lilly go forward [19][20]. (updated 2026-09-14)

The compounders pushed back. In January 2026 Strive sued Lilly and Novo Nordisk for antitrust violations in the Western District of Texas, alleging the two manufacturers used exclusive telehealth agreements to shut compounders out. On August 6, 2026 Judge Micaela Alvarez dismissed the case, holding that Strive had not plausibly alleged a relevant product market, since compounded GLP-1s are only available when a prescriber determines an approved drug cannot meet a patient-specific need [15].

Has the rivalry made anything cheaper?

Yes, though competition is only part of the reason.

Lilly cut insulin list prices 70% in March 2023 and capped out-of-pocket costs at $35. It launched Zepbound single-dose vials at $399 and $549 in August 2024, prompting Senator Bernie Sanders to call it “a modest step forward” while noting that Lilly had simultaneously raised its savings-card price from $550 to $650 and had not touched Mounjaro, which he said cost $1,069 a month in the United States against $485 in the United Kingdom and $94 in Japan [16].

Then came the November 2025 agreement, which pushed Medicare and Medicaid pricing to around $245 with a $50 copay and cut self-pay prices again.

The direction of travel is clearly downward. In the second quarter of 2026, Lilly’s globally realized prices fell 13%, and outside the United States they fell 36%. The company grew anyway, because volume rose 60% [17]. That is what a price war looks like when demand is still expanding faster than prices are falling.

What does this mean if you take one of these drugs?

Very little of a market-share fight should change what you do. Which medicine suits you depends on your medical history, what your insurance covers, what side effects you can tolerate and what your provider recommends, not on whose quarterly numbers were larger.

Two practical things do follow. Prices in this category are moving quickly and in your favor, so any price you read, including in this article, should be checked against the current published price before you act on it. And the comparative claims in television advertising from both companies are now the subject of active litigation, which is a reasonable prompt to treat “loses more weight than” claims in any ad with care.

Sources

Questions people ask

Who is winning, Eli Lilly or Novo Nordisk?

Lilly, on almost every measure except pills. Lilly's own second-quarter 2026 earnings presentation put its share of the US obesity and diabetes incretin market at 60.9% against Novo Nordisk's 38.8%. In pills it is the reverse: Novo's Wegovy pill took about $496 million in the second quarter of 2026 against $98 million for Lilly's Foundayo.

How did Lilly catch up when Novo Nordisk was first?

Three things. It built factories in 2020 before its drug was approved, so it could supply demand when it arrived. It ran a head-to-head trial, SURMOUNT-5, that showed more weight loss with tirzepatide than semaglutide. And it opened its own direct-to-patient sales channel, LillyDirect, in January 2024.

What did Eli Lilly agree with the Trump administration?

On November 6, 2025 Lilly agreed that Zepbound, and orforglipron if approved, would cost Medicare beneficiaries no more than $50 a month, a change Lilly said could start as early as April 1, 2026 and that took effect when Medicare's coverage of these drugs for obesity began on July 1, 2026, reaching roughly 40 million people. It also cut LillyDirect self-pay prices and offered several other medicines at 50% to 60% off list. In return it received three years of relief from new pharmaceutical tariffs.

Why is Novo Nordisk suing Eli Lilly?

Novo filed a false-advertising suit in New Jersey federal court on July 21, 2026, arguing that Lilly's ads compare the highest doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic while leaving out newer, stronger doses Novo has since had approved. Lilly says its advertising rests on SURMOUNT-5, the only head-to-head trial of the two drugs, and is defending the case.

Is Zepbound better than Wegovy?

In the one head-to-head trial of the injections, SURMOUNT-5, tirzepatide produced more weight loss than semaglutide, 20.2% against 13.7%. But that trial tested Zepbound's highest doses against Wegovy doses that were the highest available at the time, and Novo has since had a stronger 7.2 mg dose approved. No trial has compared the highest approved doses of both. Which drug suits any individual is a decision for them and their healthcare provider.

Did the FDA warn Eli Lilly about its advertising?

Yes. On September 9, 2025 the FDA sent Lilly three warning letters over promotional videos for Zepbound and Mounjaro, including one covering a 2024 Oprah Winfrey primetime special, saying they omitted or minimized serious risks. Lilly responded that the interviews were conducted by independent media and were not advertisements.

Why has Eli Lilly sued telehealth companies?

Lilly filed suits in April 2025 against Fella Health, Willow Health, Henry Meds and Mochi Health, alleging they marketed mass-produced compounded tirzepatide as personalized medicine. Results have been mixed: one case was dismissed with prejudice, others have been allowed to proceed.

Has competition made these drugs cheaper?

Prices have come down, though competition is only part of the reason. Self-pay prices now start at $149 a month for pills from both companies, and the most-favored-nation agreements announced in November 2025 set Medicare payment at about $245 a month with a $50 patient copay.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.